Cue Biopharma (CUE) has disclosed a new risk, in the Share Price & Shareholder Rights category. Cue Biopharma faces a significant risk ...

Shares in Palantir Technologies Inc were up more than 6% on Friday, hitting a record high, after it announced late on ...

The CEOs of Germany's Commerzbank and UniCredit had an extensive talk for the second time since Italy's No. 2 bank disclosed ...

Following the reverse share split the Company will have approximately 719,367 outstanding shares out of which approximately 520,290 will be ...

At the annual meeting of stockholders held on November 11, 2024, Polar Power’s stockholders granted authority to the Board of Directors (the “Board”) to effect, in its discretion prior to December 31, ...

Nvidia (NVDA) invests in digital infrastructure solutions developer, Applied Digital (APLD), alongside other tech companies, ...

(Reuters) -Pony AI is seeking a valuation of up to $4.48 billion in its U.S. initial public offering, it said on Thursday, as ...

Pony AI is seeking a valuation of up to $4.48 billion in its U.S. initial public offering, it said on Thursday, as the Chinese self-driving firm moves ahead with its long-sought plan for a New York ...

CyberArk Software's Q3 results highlight strong growth and strategic acquisition of Venafi. See why CYBR stock is gaining ...

According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...

Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectableCompany ...

Lete-cel is being investigated for the treatment of synovial sarcoma and myxoid/round cell liposarcoma (MRCLS) in the pivotal IGNYTE-ESO (NCT03967223) trial in patients who received prior ...